Qin C. Ji

Qin C. Ji

Auto-generated profile, based on publicly available information

Qin C. Ji

Bioanalytical Sciences, Research & Development, Bristol-Myers Squibb Co., Princeton, NJ 08543, USA

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2011 in Analytical Chemistry
Verified
Journal Article
Closed access
GLGuowen Liu
Guowen Liu
QJQin C. Ji
Qin C. Ji
MJMohammed Jemal
Mohammed Jemal
ATAdrienne A. Tymiak
Adrienne A. Tymiak
MAMark E. Arnold
Mark E. Arnold

1 April 2015 in Journal of Chromatography B
Verified
Journal Article
Closed access
NZNaiyu Zheng
Naiyu Zheng
LYLong Yuan
Long Yuan
QJQin C. Ji
Qin C. Ji
HMHeidi Mangus
Heidi Mangus
YSYan Song
Yan Song
MAMark E. Arnold
Mark E. Arnold

1 October 2013 in Bioanalysis
Verified
Journal Article
Closed access
LYLong Yuan
Long Yuan
AAAnne-Françoise Aubry
Anne-Françoise Aubry
MAMark E Arnold
Mark E Arnold
QJQin C Ji
Qin C Ji
Background: Increasing assay sensitivity is critical for promoting the application of LC–MS/MS quantitative bioanalysis of therapeutic proteins. A sample processing method that can selectively remove the abundant background peptides in the serum tryptic digests and retain the target peptides can greatly improve the assay sensitivity. Results: Mixed-mode strong-cation exchange SPE was systematically investigated as an orthogonal sample separation technique to reversed-phase UHPLC for the analysis of a test monoclonal antibody, BMS-986012, in monkey serum after pellet digestion. Strong cation exchange SPE efficiently removed most of the background peptides and reduced the matrix effect and background level in the monitored mass transition channels. As a result, improved sensitivity was observed for the surrogate peptides VVSV and SLIY. Conclusion: This orthogonal approach provides a simple and easy-to-develop sample preparation method that can selectively remove most background peptides and extract the target peptides, therefore, improving the LC–MS/MS assay sensitivity.

12 April 2011 in Rapid Communications in Mass Spectrometry
Verified
Journal Article
Closed access
PDF file
GLGuowen Liu
Guowen Liu
HSHeidi M. Snapp
Heidi M. Snapp
QJQin C. Ji
Qin C. Ji

1 August 2012 in Bioanalysis
Verified
Journal Article
Closed access
QJQin C Ji
Qin C Ji
GLGuowen Liu
Guowen Liu
CDCelia J D‘aRienzo
Celia J D‘aRienzo
TOTimothy V Olah
Timothy V Olah
MAMark E Arnold
Mark E Arnold
In the last several years, dried blood spot (DBS) sampling has re-emerged and attracted a great interest in the pharmaceutical industry as a microsampling technology for drug discovery and development studies. Although significant progress has been made to understand strengths and weaknesses of the technique, many organizations are still at the evaluation stage and experimental observations have resulted in more questions being raised as to whether there is a real future for this technology in pharmaceutical research, especially in support of pharmacokinetic studies. This article summarizes recently gained knowledge against the originally projected advantages of this technique, discusses some practical challenges that need to be overcome before DBS can be widely applied in drug development studies, and highlights some specific study types where DBS can be applied with a good benefit:risk ratio. The authors hope this article can stimulate further discussions about what are the next steps for DBS.

1 May 2008 in Journal of Chromatography A
Verified
Journal Article
Closed access
HJHongliang Jiang
Hongliang Jiang
YLYinghe Li
Yinghe Li
MPMary Pelzer
Mary Pelzer
MCMichelle J. Cannon
Michelle J. Cannon
CRChristopher Randlett
Christopher Randlett
QJQin C. Ji
Qin C. Ji